Pfizer’s breast cancer drug Ibrance, or palbociclib, is too expensive to justify its use on Britain’s state-run health service, the country’s healthcare cost-effectiveness watchdog said on Friday.
The National Institute for Health and Care Excellence (NICE) said in draft guidance that although the medicine was likely to offer some improvement in overall survival, this could not be quantified from clinical trials.
Source: Reuters
Filed Under: Drug Discovery